Bruton's Tyrosine Kinase Inhibitors: Recent Updates.

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders. The BTK receptor is expressed in several hematopoietic cells such as macrophages, neutrophils, mast cells, and osteoclasts. Similarly, the BTK receptor is involved in signaling pathways such as chemokine receptor signaling, Toll-like receptor signaling, and Fc receptor signaling. Due to their unique mechanism, these agents provide a diverse utility in a variety of disease states not limited to the field of malignant hematology and are generally well-tolerated.

Citation

Amneh Fares, Carlos Carracedo Uribe, Diana Martinez, Tauseef Rehman, Carlos Silva Rondon, Jose Sandoval-Sus. Bruton's Tyrosine Kinase Inhibitors: Recent Updates. International journal of molecular sciences. 2024 Feb 12;25(4)

Mesh Tags

Substances

PMID: 38396884

search → result